Rhythm Pharmaceuticals公布多项新数据:展示MC4R激动剂在获得性下丘脑肥胖、Bardet-Biedl综合征及Prader-Willi综合征中的研究成果于ENDO 2026

美股速递
Jun 16

Rhythm Pharmaceuticals Inc. 宣布,将在ENDO 2026大会上展示其MC4R激动剂针对获得性下丘脑肥胖、Bardet-Biedl综合征以及Prader-Willi综合征的多项最新研究数据。这些报告将揭示该疗法在多种罕见遗传性肥胖疾病中的最新进展与潜在疗效。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10